

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EDDING GENOR GROUP HOLDINGS LIMITED

亿腾嘉和醫藥集團有限公司

(formerly known as Genor Biopharma Holdings Limited

嘉和生物藥業(開曼)控股有限公司)

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6998)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 26 JUNE 2026

Reference is made to the circular of Edding Genor Group Limited (the “**Company**”) dated 16 April 2026 (the “**Circular**”). Unless the context otherwise requires, terms used in this announcement shall have the same meanings as defined in the Circular.

At the annual general meeting (the “**AGM**”) of the Company held at 55/F, Tower 1, Plaza 66, No. 1266 Nanjing West Road, Jing’an District, Shanghai, China on Friday, 26 June 2026 at 10:00 a.m., all the proposed resolutions as set out in the notice of the AGM dated 16 April 2026 (the “**AGM Notice**”) were taken by poll.

As at the date of the AGM, (a) the total number of shares of the Company in issue was 2,014,041,774; (b) the Company was holding 23,293,500 treasury Shares which should be excluded from the total number of Shares entitling the Shareholders to attend and vote on the resolutions at the AGM, and the Company has not exercised the voting rights of the treasury Shares at the AGM; and (c) there was no repurchased Shares which are pending cancellation and should be excluded from the total number of issued Shares for the purpose of the AGM.

Save as disclosed in this announcement, to the best knowledge, information and belief of the Directors: (a) there were no Shares entitling the holder to attend and abstain from voting in favour of the resolutions at the AGM as set out in rule 13.40 of the Listing Rules; (b) no Shareholder was required under the Listing Rules to abstain from voting on the resolutions at the AGM; and (c) none of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the AGM.

Accordingly, the total number of Shares entitling the holder to attend and vote on the resolutions at the AGM was 1,990,748,274 Shares as at the date of the AGM.

The AGM has been held pursuant to the requirements of the Cayman Companies Act and the Articles of Association. The AGM was chaired by Mr. Ni Xin, the chairman of the Company.

The Directors namely Mr. Ni Xin, Dr. Han Shuhua, Dr. David Guowei Wang, Mr. Yu Tieming, Dr. Xu Qing, Mr. Chen Wen and Ms. Zheng Jingjing attended the AGM in person or by electronic means.

The Company's share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.

POLL RESULTS OF THE ANNUAL GENERAL MEETING

The poll results of the resolutions proposed at the AGM are set out as follows:

Ordinary Resolutions		Number of votes (%)	
		For	Against
1.	To consider and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors (the “ Directors ”) and auditor (the “ Auditor ”) of the Company for the year ended 31 December 2025.	1,308,034,430 (100.000000%)	0 (0.000000%)
2.	(a) To re-elect Mr. Ni Xin as an executive Director.	1,307,095,430 (99.928213%)	939,000 (0.071787%)
	(b) To re-elect Dr. Han Shuhua as an executive Director.	1,308,034,430 (100.000000%)	0 (0.000000%)
	(c) To re-elect Dr. David Guowei Wang as a non-executive Director.	1,307,095,430 (99.928213%)	939,000 (0.071787%)
	(d) To re-elect Dr. Xu Qing as an independent non-executive Director.	1,308,034,430 (100.000000%)	0 (0.000000%)
	(e) To re-elect Mr. Chen Wen as an independent non-executive Director.	1,308,034,430 (100.000000%)	0 (0.000000%)
	(f) To re-elect Ms. Zheng Jingjing as an independent non-executive Director.	1,308,034,430 (100.000000%)	0 (0.000000%)
	(g) To authorize the board of Directors (the “ Board ”) to fix the respective Directors’ remuneration.	1,308,034,430 (100.000000%)	0 (0.000000%)
3.	To re-appoint Ernst & Young as the Auditor for the year ending 31 December 2026 and to authorize the Board to fix their remuneration.	1,308,034,430 (100.000000%)	0 (0.000000%)
4.	To grant a general and unconditional mandate to the Directors to repurchase shares of the Company not exceeding 10% of the total number of issued shares of the Company (excluding any treasury shares of the Company) as at the date of passing of this resolution.	1,308,034,430 (100.000000%)	0 (0.000000%)

Ordinary Resolutions		Number of votes (%)	
		For	Against
5.	To grant a general and unconditional mandate to the Directors to issue, allot and deal with additional shares (including any sale and transfer of treasury shares) of the Company not exceeding 20% of the total number of issued shares of the Company (excluding any treasury shares of the Company) as at the date of passing of this resolution.	1,305,265,930 (99.788347%)	2,768,500 (0.211653%)
6.	Conditional upon resolutions numbered 4 and 5 being passed, to extend the general mandate granted to the Directors to issue, allot and deal with additional shares in the capital of the Company by adding the aggregate number of shares repurchased by the Company.	1,305,265,930 (99.788347%)	2,768,500 (0.211653%)

* The full text of the resolutions is set out in the AGM Notice

In respect of each of the above ordinary resolutions numbered 1 to 6, as more than half of the votes of the voting Shareholders (including their proxies and authorized representatives) were cast in favor of each of these resolutions, all these resolutions were duly passed as ordinary resolutions.

By order of the Board
Edding Genor Group Holdings Limited
Mr. Ni Xin
Chairman and Executive Director

Hong Kong, 26 June 2026

As of the date of this announcement, the Board comprises Mr. Ni Xin and Dr. Han Shuhua as executive Directors; Dr. David Guowei Wang and Mr. Yu Tieming as non-executive Directors; and Dr. Xu Qing, Mr. Chen Wen and Ms. Zheng Jingjing as independent non-executive Directors.